Table 4.
Clinical Outcomes of Patients with ESBL or Non-ESBL Urosepsis
| Group; Median (IQR) or No. (%) of Patients | |||
|---|---|---|---|
|
|
|||
| Outcome | ESBL Urosepsis (n = 58) | Non-ESBL Urosepsis (n = 118) | p Value |
| Duration of hospital admission (days) | 11 (6–27) | 7 (3–13) | 0.003 |
| Total duration of treatment (days) | 14 (9–28) | 13 (9–17) | 0.048 |
| Received appropriate treatment within 24 h | 48 (82.8) | 112 (94.9) | 0.012 |
| Time to appropriate treatment (h) | 4 (1.5–18) | 2.5 (1–7.8) | 0.067 |
| All-cause mortality or palliative measures only on discharge | 7 (12.1) | 4 (3.4) | 0.042 |
ESBL = extended-spectrum β-lactamase, IQR = interquartile range.